Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.49 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.48 |
| ▸ | ALPI | P09923 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | XIAP | P98170 | 1/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.46 |
| ▸ | LAP3 | P28838 | 3/20 | 0.46 |
| ▸ | ANPEP | P15144 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27863404 | 1.00 | EPHX1 (0.52) | EPHX1CSNK1ETRPA1ALPIPKM | |
| SCHEMBL4441102 | 1.00 | EPHX1 (0.52) | EPHX1CSNK1ETRPA1ALPIPKM | |
| SCHEMBL6425554 | 0.87 | EPHX1 (0.62) | EPHX1CSNK1ETRPA1ALPIPKM | |
| Hydrochloric Acid SCHEMBL9388352 | 0.85 | EPHX1 (0.60) | EPHX1CSNK1ETRPA1ALPIPKM | |
| SCHEMBL4502384 | 0.83 | EPHX1 (0.58) | EPHX1CSNK1ETRPA1ALPIPKM | |
| SCHEMBL8690233 | 0.83 | EPHX1 (0.58) | EPHX1CSNK1ETRPA1ALPIPKM | |
| SCHEMBL296417 | 0.83 | EPHX1 (0.52) | EPHX1CSNK1ETRPA1ALPIPKM | |
| SCHEMBL27199623 | 0.83 | EPHX1 (0.58) | EPHX1CSNK1ETRPA1ALPIPKM | |
| SCHEMBL11091491 | 0.83 | EPHX1 (0.58) | EPHX1CSNK1ETRPA1ALPIPKM | |
| SCHEMBL724380 | 0.82 | ANPEP (0.59) | EPHX1CSNK1ETRPA1ALPIPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102399161-B | Method for preparing chloramphenicol | WUHAN WU PHARMACEUTICAL TECHNOLOGY CO LTD | 2014-07-16 | — | — | CN | disclosed |
| CN-102399160-B | Method for synthesizing chloramphenicol | WUHAN WU PHARMACEUTICAL TECHNOLOGY CO LTD | 2014-07-16 | — | — | CN | disclosed |
| CN-102399160-A | Synthesis method of chloramphenicol | WUHAN WU PHARMACEUTICAL TECHNOLOGY CO LTD | 2012-04-04 | — | — | CN | disclosed |
| CN-102399161-A | Preparation method of chloramphenicol | WUHAN WU PHARMACEUTICAL TECHNOLOGY CO LTD | 2012-04-04 | — | — | CN | disclosed |
| US-7618990-B2 | 4-[2-(4,4-Dimethyl-2-thioxo-1,3-oxazolidin-3-yl)-1,3-thiazol-4-yl]benzonitrile; progesterone receptor (PR); contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, hormone replacement therapy | WYETH (US) | 2009-11-17 | — | — | US | disclosed |
| EP-2054410-A2 | OXAZOLIDONE DERIVATIVES AS PR MODULATORS | Wyeth (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20080045556-A1 | Oxazolidone derivatives as PR modulators | WYETH (US) | 2008-02-21 | — | — | US | disclosed |
| WO-2008021331-A2 | OXAZOLIDONE DERIVATIVES AS PR MODULATORS | WYETH (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045556-A1 | Oxazolidone derivatives as PR modulators | MC2R, NPY1R, PRLHR | EPHX1 3774/4885CSNK1E 275/4885TRPA1 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.